Streetwise Articles


Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

  ()
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

  ()
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. read more >

Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. read more >

Biotech Round-Up: M&As, Financings and Immuno-Oncology

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. read more >

Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal

  ()
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. read more >

Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data. read more >

Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status. read more >

Biotech Announces Positive Topline Data in Tourette Syndrome

Research Report
  ()
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. read more >

CMS Unexpectedly Issues Product Billing Code to Biotech

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm. read more >

RNAi Therapeutics Developer Reports Positive Amyloidosis Data

Research Report
  ()
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. read more >

Biotech Delivers 'Excellent' Phase 2 Data

Contributed Opinion
  ()
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. read more >

Medical Device Firm Posts 'Strong Performance' Globally in Q4/17

Research Report
  ()
The company performed strongly in the U.S. and the Asia Pacific region. read more >

Regrouped Biotech's Stock Price Could See Fifteenfold Increase

Research Report
  ()
A recent conference call provided clinical and financial updates. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >
Management Q&A: View from the Top

Biotech Advances Treatments for Liver Disease, Pain, Mental Illness

Managment Q&A: View from the Top
  ()
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018. read more >

Two Biotechs Earn Analyst's Top Pick Ranking

  ()
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well. read more >

Price Target on Biotech Is a 700% Potential Increase

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. read more >

Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'

Research Report
  ()
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. read more >

Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3

Research Report
  ()
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. read more >

Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside

Research Report
  ()
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. read more >

Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet

Research Report
  ()
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. read more >

Exciting Biotech Stock Now Breaking Out of Large Base

Contributed Opinion
  ()
Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy. read more >

Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

Research Report
  ()
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential. read more >

Fund Manager Names Three Small-Caps with Strong Growth Profiles

  ()
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects. read more >
Showing Results: 26 to 50 of 63 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research